ANI Pharmaceuticals (ANIP) Q3 2024 earnings summary

Executive summary

• Achieved record Q3 2024 revenues of $148.3 million, up 13% year-over-year, driven by strong growth in Cortrophin Gel, generics, and the addition of ILUVIEN and YUTIQ from the Alimera acquisition.

• Completed transformative acquisition of Alimera Sciences on September 16, 2024, expanding the rare disease portfolio and international presence.

• Implemented a new capital structure, expected to reduce annualized interest expense by $39 million.

• Expanded and cross-trained a 45-person ophthalmology sales force to promote all rare disease products.

• Raised 2024 guidance for net revenues, adjusted EBITDA, and adjusted EPS.

Financial highlights

• Q3 2024 total/net revenues: $148.3 million (+13% YoY); Cortrophin Gel revenues: $52.6 million (+77% YoY); generics revenues: $78.2 million (+11% YoY); established brands and other: $13.7 million (-57% YoY).

• Q3 2024 net loss: $(24.2) million; adjusted non-GAAP EBITDA: $35.1 million; adjusted non-GAAP EPS: $1.34 (up from $1.27 YoY).

• Gross margin: 57.5% GAAP (down from 63.5% YoY); non-GAAP gross margin: 59.9% (down from 63.7% YoY).

• SG&A expenses rose 88.2% YoY to $79.1 million in Q3, driven by Alimera transaction costs and integration.

• Ended Q3 with $145 million in cash and $641.3 million in debt.

Outlook and guidance

• Raised full-year 2024 net revenue guidance to $594–$602 million (22–24% YoY growth); adjusted non-GAAP EBITDA: $149–$153 million; adjusted non-GAAP EPS: $4.90–$5.05.

• Cortrophin Gel revenue guidance increased to $196–$200 million (75–78% YoY growth); ILUVIEN and YUTIQ expected to contribute $30–$32 million post-acquisition in 2024.

• Adjusted non-GAAP gross margin expected at high end of 61–62% range.

• Annual GAAP effective tax rate now expected in the mid-single digits due to non-deductible acquisition expenses.

• Sufficient liquidity for at least the next 12 months, supported by new credit facility and convertible notes.